Intro

This chapter discusses the latest findings from the ASCO GU conference on innovative treatments for kidney and bladder cancer. It specifically highlights a pivotal phase three trial of a triplet combination therapy for kidney cancer, detailing its efficacy in comparison to a placebo and addressing challenges related to treatment exposure and patient responses.